Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 10/20 | 0.70 |
| ▸ | NR1H3 | Q13133 | 10/20 | 0.70 |
| ▸ | POLA1 | P09884 | 4/20 | 0.61 |
| ▸ | SOD1 | P00441 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | APEX1 | P27695 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31678855 | 1.00 | NR1H2 (0.70) | NR1H2NR1H3POLA1SOD1POLB | |
| SCHEMBL20561209 | 0.93 | POLA1 (0.63) | NR1H2NR1H3POLA1SOD1CYP2C9 | |
| SCHEMBL29295276 | 0.93 | POLA1 (0.63) | NR1H2NR1H3POLA1SOD1CYP2C9 | |
| SCHEMBL20561208 | 0.93 | POLA1 (0.63) | NR1H2NR1H3POLA1SOD1CYP2C9 | |
| SCHEMBL20560979 | 0.92 | POLA1 (0.73) | NR1H2NR1H3POLA1POLBAPEX1 | |
| SCHEMBL13208236 | 0.84 | LMNA (0.62) | NR1H2NR1H3POLA1SOD1POLB | |
| Acetyl Podocarpic Acid Anhydride SCHEMBL31364127 | 0.82 | NR1H2 (1.00) | NR1H2NR1H3POLA1SOD1PDE4D | |
| Acetyl Podocarpic Acid Anhydride SCHEMBL5538089 | 0.82 | NR1H2 (1.00) | NR1H2NR1H3POLA1SOD1PDE4D | |
| SCHEMBL20561210 | 0.81 | POLA1 (0.51) | NR1H2NR1H3POLA1POLBAPEX1 | |
| SCHEMBL6312669 | 0.80 | NR1H2 (1.00) | NR1H2NR1H3POLA1SOD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180334426-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDES AND PROTEIN CONJUGATES THEREOF | REGENERON PHARMACEUTICALS, INC. (US) | 2018-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180334426-A1 | BIS-OCTAHYDROPHENANTHRENE CARBOXAMIDES AND PROTEIN CONJUGATES THEREOF | NR1H4, NR1H3, OGFR | NR1H2 4/4885NR1H3 2/4885POLA1 2752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.